PHILADELPHIA, October 27 2022 (Newswire.com)— Senzo, a global life sciences company
developing high accuracy, low-cost, point-of-care diagnostic technologies, today announced a
partnership with BARDA, part of the Administration for Strategic Preparedness and Response
(ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing
Senzo’s Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug
Administration (FDA) Emergency Use Authorization (EUA) to market. This contract follows
Senzo’s recent announcements about the receipt of ISO 13485:2016 certification, and
completing a $2 million Pre-Series A financing led by BioAdvance, to apply the ALF technology
to other targets such as Flu A/B, Tuberculosis, HIV, C. diff, Sexual Health, and Hepatitis C.
Senzo’s core innovation is its Amplified Lateral Flow (ALF) technology which significantly
increases the sensitivity of a traditional-format lateral flow test, while maintaining specificity. The
end result is a fast, low-cost, easy-to-use lateral flow test with the same accuracy as a PCR test,
the diagnostics industry's gold standard test. The ability to incorporate amplification into a lateral
flow test has long been a goal for diagnostics test makers but one which has proven difficult to
achieve due to the tendency for amplified tests to return false positives. Senzo recently
announced results from a blinded, 3rd-party R&D study demonstrating that its Amplified Lateral
Flow (ALF) COVID-19 antigen test was 100% accurate in concordance with PCR testing, even
in cases with very low viral levels, which could allow for substantially better and earlier detection
of virus compared to current lateral flow tests.
“The faster we can accurately diagnose, the sooner we can take action, begin treatment, and
the better the patient outcome. Creating a low-cost, user-friendly diagnostic test which delivers
PCR accuracy at the point of care, without the need to send a sample to a laboratory, will
improve healthcare— it’s that simple. BARDA’s support of our ALF technology will be
instrumental in helping us advance our ultimate goal of bringing ALF tests to market,” said
Jeremy Stackawitz, CEO of Senzo.
This project has been supported in whole or in part with federal funds from the Department of
Health and Human Services; Administration for Strategic Preparedness and Response;
Biomedical Advanced Research and Development Authority (BARDA), under contract number
75A50122C00041.
About Senzo:
Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible
testing products. Senzo was founded with the vision of utilizing novel technologies, with a focus
on enhanced sensitivity, to create mobile, point-of-care and self-testing products and devices
with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare
professionals and patients need it most. Senzo is creating game-changing products and
systems which bring testing to the patient, eliminating the need for the current slow, expensive
central-lab testing paradigms. With insights generated at the point of care, patients can make
better decisions faster, and healthcare professionals can identify life-threatening diseases at an
earlier stage, improving treatment outcomes and saving lives. www.senzo.com.